FDA approves 1st medicine with digestible sensor — 4 key notes

The FDA approved Otsuka Pharmaceutical's and Proteus Digital Health's Abilify Mycite system, an aripiprazole tablet with a digestible sensor to monitor drug ingestion and treat mental illness among others.

Here's what you should know:

1. The system includes the Abilify Mycite, the Mycite patch, the Mysite app and a web-based portal for providers.

2. Abilify Mycite tracks ingestion. The pill was designed to improve patient compliance. The sensor will transmit to the physician and user when the pill was taken.

3. Otsuka is rolling out the system in limited quantities so providers, health plans and the company can "[learn] from these patients' experience."

4. Otsuka will take the data from the limited rollout to enhance the system before launching a broader go-to-market plan.

Otsuka Pharmaceutical's President Tatsuo Higuchi said in a release, "This approval marks a potentially transformative juncture in our more than 25 years of experience in the field of mental health therapies. We remain committed to making a difference for individual patients and their care team by helping address the challenge of objectively measuring medication ingestion."

More articles on supply chain:
Common deficiencies AAAASF cites & how to fix them — continuing discussion on keeping up with documentation
'Data is the crux of outpatient TJR' — 2 physicians share strategies to build strong data platforms in ASCs
15 ASCs & outpatient facilities achieving accreditation — October 2017

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months